Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05981209
Title Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Abdullah Khan
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.